Core Viewpoint - Aomei Medical reported its semi-annual results for 2025, showing positive growth in both revenue and net profit [1] Financial Performance - The company achieved an operating income of 1.676 billion yuan, representing a year-on-year increase of 5.99% [1] - The net profit attributable to shareholders of the listed company was 200 million yuan, reflecting a year-on-year growth of 6.87% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 185 million yuan, with a year-on-year increase of 8.87% [1] - Basic earnings per share were reported at 0.3160 yuan [1]

2025 年半年度报告 奥美医疗用品股份有限公司 股票简称：奧美医疗 股票代码：002950.SZ 1第一节 重要提示、目录和释义 奥美医疗用品股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人崔金海、主管会计工作负责人黄铁柱及会计机构负责人(会计 主管人员)陈同山声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本年度报告涉及未来计划等前瞻性描述，不构成公司对投资者的实质承 诺，请投资者注意投资风险。 （一）外销收入占比较大风险 公司的外销出口目的地区主要集中在北美和欧洲等发达地区市场，外销 业务受国家出口政策、出口目的地国进口政策与经济状况、货币汇率以及国 际医用敷料市场变动等多方面因素的影响。如果外销业务发生波动，公司经 营业绩将受到一定影响。 风险应对措施：（1）加大中东、亚非拉等新兴市场的开拓，增加公司抵 御海外市场集中风险的能力；（2）加大国内医用品市场的开拓， ...

Core Viewpoint - As of August 18, 2025, Aomei Medical (002950) closed at 9.67 yuan, down 1.02%, with a trading volume of 90,500 lots and a transaction value of 87.917 million yuan [1] Group 1: Financial Performance - Aomei Medical's Q1 2025 report shows a main revenue of 759 million yuan, a year-on-year increase of 1.64% [2] - The net profit attributable to shareholders is 86.503 million yuan, a year-on-year decrease of 7.86% [2] - The net profit after deducting non-recurring gains and losses is 74.065 million yuan, a year-on-year decrease of 11.39% [2] - The company's debt ratio stands at 32.54% [2] - The gross profit margin is 30.52% [2] Group 2: Market Position and Ratios - Aomei Medical's total market value is 6.124 billion yuan, compared to the industry average of 12.121 billion yuan, ranking 60th out of 123 [2] - The company's net assets are 3.526 billion yuan, while the industry average is 3.9 billion yuan, ranking 43rd out of 123 [2] - The price-to-earnings ratio (P/E) is 17.7, significantly lower than the industry average of 78.16, ranking 8th out of 123 [2] - The price-to-book ratio (P/B) is 1.76, compared to the industry average of 4.05, ranking 26th out of 123 [2] - The company's net profit margin is 11.42%, slightly above the industry average of 10.86%, ranking 66th out of 123 [2] - Return on equity (ROE) is 2.51%, compared to the industry average of 1.25%, ranking 31st out of 123 [2] Group 3: Capital Flow Analysis - On August 18, 2025, the net outflow of main funds was 4.3196 million yuan, accounting for 4.91% of the total transaction value [1] - The net inflow of speculative funds was 6.1971 million yuan, accounting for 7.05% of the total transaction value [1] - Retail investors experienced a net outflow of 1.8775 million yuan, accounting for 2.14% of the total transaction value [1]

Core Viewpoint - Aomei Medical's stock closed at 9.74 yuan, down 1.32%, with a rolling PE ratio of 17.07 times, significantly lower than the industry average of 55.76 times, indicating potential undervaluation in the medical device sector [1][3]. Company Overview - Aomei Medical specializes in the research, production, and sales of medical consumables, disposable medical devices, infection protection products, and home care products [2]. - The company's main products include surgical and wound care, infection protection, advanced dressings, and hygiene care [2]. Industry Performance - Aomei Medical's PE ratio ranks 37th in the medical device industry, which has an average PE of 55.76 times and a median of 39.14 times [1][3]. - The company has shown a decline in net profit by 7.86% year-on-year, despite a revenue increase of 1.64% in the latest quarterly report [3]. Recent Achievements - Aomei Medical has received multiple accolades, including being listed among the top 100 private manufacturing enterprises in Hubei and recognized for its intelligent manufacturing projects [2]. - The company was awarded the "2022 Annual China Industry-University-Research Cooperation Innovation Achievement Excellent Award" and ranked among the top 50 medical device companies in terms of revenue [2].

8月13日的资金流向数据方面，主力资金净流出687.86万元，占总成交额5.75%，游资资金净流入452.67 万元，占总成交额3.78%，散户资金净流入235.19万元，占总成交额1.96%。 证券之星消息，截至2025年8月13日收盘，奥美医疗(002950)报收于9.87元，下跌1.4%，换手率2.69%， 成交量12.15万手，成交额1.2亿元。 近5日资金流向一览见下表： | 指标 | 跑美医疗 | 医疗器械行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 62.5亿元 | 120.64亿元 | 58 123 | | 净资产 | 35.26亿元 | 38.99亿元 | 43 123 | | 净利润 | 8650.27万元 | 7927.36万元 | 29 123 | | 市盈率(动) | 18.06 | 70.48 | 9 123 | | 市净率 | 1.8 | 4.02 | 28 123 | | 毛利率 | 30.52% | 51.34% | 104 123 | | 净利率 | 11.42% | 10.86% | 66 123 | | ROE | 2. ...

Core Insights - The report highlights the significant role of CFOs in listed companies, with the total compensation for A-share CFOs reaching 4.27 billion yuan in 2024, averaging 814,800 yuan per year [1][2] Group 1: CFO Compensation Overview - The average annual salary for CFOs in the A-share medical device sector is 908,600 yuan [2] - The distribution of CFO salaries shows that 24% earn below 500,000 yuan, 42% earn between 500,000 and 1 million yuan, 29% earn between 1 million and 2 million yuan, and 5% earn above 2 million yuan [2] - The top three highest-paid CFOs are Dai Zhenhua from Huatai Medical at 2.70 million yuan, Rui Chenwei from Nanwei Medical at 2.65 million yuan, and Wu Jinhong from Guoke Hengtai at 1.77 million yuan [2] Group 2: CFO Demographics - The age distribution of CFOs shows that those aged 40-50 make up 57%, while 32% are over 50, and 11% are 40 or younger [1] - The youngest CFO is 31 years old, while the oldest is 60 years old [1] - In terms of educational background, 16% of CFOs have an associate degree, 66% hold a bachelor's degree, 16% have a master's degree, and only 2% possess a doctoral degree [1] Group 3: Salary Changes - Among CFOs with over two years of tenure, the largest salary decrease was observed for Kong Xiangqian from Aidi Te, with a decline of 16.86% year-on-year [2] - Conversely, the largest salary increase was for Song Yizhao from Shandong Glass, with a rise of 144.86% year-on-year [2]

截至2025年8月1日收盘，奥美医疗(002950)报收于9.36元，上涨1.08%，换手率1.25%，成交量5.65万 手，成交额5282.44万元。 当日关注点 交易信息汇总 8月1日，奥美医疗的资金流向如下：主力资金净流入544.14万元；游资资金净流出336.92万元；散户资 金净流出207.22万元。 股本股东变化 公司公告汇总关于持股5%以上股东权益变动暨披露简式权益变动报告书的提示性公告 奥美医疗用品股份有限公司发布公告，陈浩华先生于2025年7月22日至7月30日通过大宗交易形式减持 7482900股公司A股股票，减持后其持有61353421股公司A股股票，持股比例变动触及5%的整数倍。本 次权益变动不涉及控股股东及一致行动人增持或减持，不会导致公司控股股东及实际控制人发生变化。 关于股份回购进展的公告 奥美医疗用品股份有限公司董事会审议通过了以集中竞价交易方式回购公司股份的议案，用于股权激励 或员工持股计划。截至2025年7月31日，公司累计回购股份1,987,400股，占总股本的0.3138%，支付总 金额为18,001,207.00元。回购价格不超过11.00元/股，资金总额不低于5,0 ...

Core Viewpoint - The company, Aomei Medical Supplies Co., Ltd., has initiated a share repurchase plan to enhance shareholder value and support employee stock ownership programs, with a total repurchase budget between RMB 50 million and RMB 100 million [2][3]. Share Repurchase Progress - As of July 31, 2025, the company has repurchased a total of 1,987,400 shares, representing 0.3138% of the total share capital, with a total expenditure of RMB 18,001,207, excluding transaction costs [3][4]. - The highest and lowest prices for the repurchased shares were RMB 9.26 and RMB 8.33 per share, respectively [3]. Shareholder Equity Change - Major shareholder Chen Haohua reduced his holdings by 7,482,900 shares through block trading from July 22 to July 30, 2025, bringing his total holdings to 61,353,421 shares [10][11]. - This reduction in shareholding does not affect the control structure of the company and complies with the previously announced reduction plan [9][11].

Summary of Key Points Core Viewpoint - The announcement details a significant reduction in shareholding by a major shareholder, Chen Haohua, of Aomei Medical Supplies Co., Ltd, through block trading, which does not affect the company's control structure or ongoing operations [1][2]. Group 1: Shareholding Changes - Chen Haohua reduced his shareholding from 68,836,321 shares (11.12%) to 61,353,421 shares (9.92%) [1]. - The reduction in shareholding touches a 5% integer multiple, indicating a notable change in ownership percentage [1]. Group 2: Compliance and Governance - The company assures that the reduction in shareholding will not lead to changes in the controlling shareholder or actual controller, nor will it impact the company's governance structure and sustainability [2]. - The announcement complies with the relevant disclosure regulations as per the guidelines for public securities [1].

Core Viewpoint - The report details a shareholding reduction by Chen Haohua, a significant shareholder of Aomei Medical Supplies Co., Ltd., due to personal financial needs, resulting in a decrease in his shareholding from 68,836,321 shares (11.12%) to 61,353,421 shares (9.92%) [4][5]. Group 1: Shareholding Changes - The shareholder reduced his stake by 7,482,900 shares through block trading at an average price of 8.47 RMB per share, representing a reduction of 1.21% of the total share capital [4][5]. - Prior to the reduction, the shareholder held 68,836,321 shares, which accounted for 11.12% of the total share capital [4][5]. - Following the reduction, the shareholder's stake fell below 10% of the total share capital [4]. Group 2: Regulatory Compliance - The report was prepared in accordance with the Company Law, Securities Law, and relevant regulations, ensuring that all necessary authorizations and approvals were obtained [1][2]. - The shareholder confirmed that the report does not contain any false records, misleading statements, or significant omissions, and he bears legal responsibility for its accuracy [2][3]. Group 3: Future Plans - The shareholder does not rule out the possibility of further increasing or decreasing his shareholding in the next 12 months, and any future changes will be disclosed in accordance with legal requirements [4][6]. - The shareholder had previously reduced his holdings by 4,214,000 shares on July 21, 2025, indicating a pattern of share reduction [5][6].